Overview

* Biote Q3 2025 revenue slightly beats analyst expectations at $48 mln

* Net income for Q3 2025 decreased to $9.2 mln from $12.7 mln last year

* Company repurchased approximately one mln shares of Class A common stock

Outlook

* Biote ( BTMD ) reiterates 2025 revenue guidance above $190 mln

* Company expects 2025 Adjusted EBITDA above $50 mln

* 2025 procedure revenue expected to decrease at high single-digit rate

Result Drivers

* PROCEDURE REVENUE DECLINE - Procedure revenue fell 10.4%, offset by 8.4% growth in dietary supplements revenue

* GROSS MARGIN IMPROVEMENT - Gross profit margin improved to 71.8% due to efficiencies from vertical integration and cost management

* INCREASED EXPENSES - Operating income decreased due to higher expenses, including the shift of the annual provider conference

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $48 mln $47.76

Revenue Beat* mln (5

Analysts

)

Q3 $12.90

Adjusted mln

EBITDA

Q3 Gross 71.80%

Margin

Q3 26.90%

Adjusted

EBITDA

Margin

Q3 $8.30

Operatin mln

g Income

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the professional information services peer group is "buy"

* Wall Street's median 12-month price target for Biote Corp ( BTMD ) is $5.46, about 47.6% above its November 4 closing price of $2.86

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)